Detail Page
The Challenge: Oncology is the fastest-moving field in medicine. General-purpose LLMs hallucinate treatment dosages or cite outdated trials. Furthermore, genomic data is highly sensitive (PHI/PII), and hospitals are increasingly resistant to sending “Raw Sequence Data” to public cloud endpoints due to data sovereignty and latency concerns.
This architecture centers on a Sovereign Small Language Model (SLM)—a 7B to 14B parameter model (like Mistral or Llama-3-Oncology) fine-tuned on the “OncoKB” database and PubMed Central. This SLM is deployed on-premises using NVIDIA NIM microservices for optimized inference.
We implement a Knowledge Graph RAG (KG-RAG). Traditional vector search misses the relationship between a gene mutation (e.g., BRAF V600E), a drug (Vemurafenib), and a specific metabolic pathway. The KG-RAG maps these entities, allowing the model to reason: “If the patient has Mutation X and has failed Treatment Y, then the next evidence-based step is Trial Z.” The retrieval layer uses Hybrid Search:
For semantic meaning (clinical notes).
For exact gene sequences and drug codes.
A Cross-Encoder model that ranks the top 5 most relevant clinical trial matches.
Because medical knowledge changes daily, the LLMOps pipeline is critical. We implement Continuous Evaluators that test the model against a “Golden Dataset” of 500 oncology cases every week. If the model’s recommendation deviates from the “Standard of Care,” the deployment is rolled back, and the RAG index is updated.
30% increase in patients matched to life-saving clinical trials.
Reduces “Literature Search” time for complex cases by 4 hours per week.
100% data residency; zero PHI leaves the hospital’s firewall.